Literature DB >> 16104942

Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism.

R John Dobbs1, Sylvia M Dobbs, Clive Weller, Ingvar T Bjarnason, Ingua T Bjarnason, Norman L Oxlade, André Charlett, Mazin A Al-Janabi, Robert W Kerwin, Robert F Mahler, Ashley B Price.   

Abstract

BACKGROUND: Neuronal damage in idiopathic parkinsonism may be in response to ubiquitous occult infection. Since peptic ulceration is prodromal, Helicobacter is a prime candidate. AIM: To consider the candidature of Helicobacter in parkinsonism with cachexia.
METHODS: We explore the relationship between being underweight and inflammatory products in 124 subjects with idiopathic parkinsonism and 195 controls, and present the first case-series evidence of efficacy of Helicobacter eradication, in parkinsonism advanced to the stage of cachexia.
RESULTS: Association of a low body mass index with circulating interleukin-6 was specific to parkinsonism (p = .002), unlike that with antibodies against Helicobacter vacuolating-toxin and cytotoxicity-associated gene product (p < .04). Marked reversibility in both cachexia and disability of idiopathic parkinsonism followed Helicobacter heilmannii eradication in one case, Helicobacter pylori eradication in another, follow-up being > or = 3.5 years. The latter presented with postprandial bloating, and persistent nausea: following eradication, radioisotope gastric-emptying returned towards normal, and upper abdominal symptoms regressed. Reversibility of their cachexia/disability contrasts with the outcome of anti-Helicobacter therapy where eradication repeatedly failed (one case), and in non-Helicobacter gastritis (three cases). Anti-parkinsonian medication remained constant. Intestinal absorption and barrier function were normal in all.
CONCLUSION: Categorization, according to presence or absence of Helicobacter infection, was a useful therapeutic tool in late idiopathic parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16104942     DOI: 10.1111/j.1523-5378.2005.00331.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  16 in total

1.  Cross-reactivity of Antibodies Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae With Heat Shock Protein 60 and ATP-Binding Protein Correlates to Reduced Mitochondrial Activity in HIBCPP Choroid Plexus Papilloma Cells.

Authors:  B Reuss; H Schroten; H Ishikawa; A R Asif
Journal:  J Mol Neurosci       Date:  2015-06-17       Impact factor: 3.444

2.  Blood profile holds clues to role of infection in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in established disease.

Authors:  André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason
Journal:  Gut Pathog       Date:  2009-11-26       Impact factor: 4.181

Review 3.  Weight loss in neurodegenerative disorders.

Authors:  N A Aziz; M A van der Marck; H Pijl; M G M Olde Rikkert; B R Bloem; R A C Roos
Journal:  J Neurol       Date:  2009-01-22       Impact factor: 4.849

4.  Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism.

Authors:  Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Ingvar T Bjarnason; Andrew J Lawson; Darren Letley; Lucy Harbin; Ashley B Price; Mohammad A A Ibrahim; Norman L Oxlade; James Bowthorpe; Daniel Leckstroem; Cori Smee; J Malcolm Plant; Dale W Peterson
Journal:  Helicobacter       Date:  2010-08       Impact factor: 5.753

5.  Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M De Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  Parkinsons Dis       Date:  2011-04-13

6.  Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  ISRN Neurol       Date:  2011-04-17

7.  Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model.

Authors:  Jayaram Lakshmaiah Narayana; Han-Ning Huang; Chang-Jer Wu; Jyh-Yih Chen
Journal:  Oncotarget       Date:  2015-05-30

8.  Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients.

Authors:  C Blaecher; A Smet; B Flahou; F Pasmans; R Ducatelle; D Taylor; C Weller; I Bjarnason; A Charlett; A J Lawson; R J Dobbs; S M Dobbs; F Haesebrouck
Journal:  Aliment Pharmacol Ther       Date:  2013-10-05       Impact factor: 8.171

9.  Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.

Authors:  Hasriza Hashim; Shahrul Azmin; Hamizah Razlan; Nafisah Wan Yahya; Hui Jan Tan; M Rizal Abdul Manaf; Norlinah Mohamed Ibrahim
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

10.  Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study.

Authors:  R John Dobbs; André Charlett; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Owens Iguodala; Cori Smee; J Malcolm Plant; Andrew J Lawson; David Taylor; Ingvar Bjarnason
Journal:  Gut Pathog       Date:  2012-10-19       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.